Cytochrome P450 2C9 Genotyping Siponimod

CPT: Call client services.
Updated on 9/9/2019
Print Share

Synonyms

  • CYP2C9
  • Mayzent
  • Novartis
  • P450 CYP2C9
  • Siponimod

Special Instructions

Samples sent to Monogram for testing.


Expected Turnaround Time

6 - 10 days


Related Documents


Specimen Requirements


Specimen

Whole blood


Volume

7 mL


Minimum Volume

3 mL


Container

Lavender-top (EDTA) tube or yellow-top (ACD) tube


Collection

Collect specimen in two lavender-top (EDTA) tubes or two yellow-top (ACD) tubes. Ship specimen at room temperature.


Storage Instructions

Room temperature, refrigerated, or frozen


Causes for Rejection

Quantity not sufficient for analysis; improper container


Test Details


Use

CYP2C9 genotype testing is required to determine candidacy and the appropriate maintenance dosage for siponimod before treatment initiation. Siponimod is contraindicated in patients who have a CYP2C9*3/*3 genotype. Refer to the siponimod package insert for more details.

CYP2C9 is gene 9 within the C subfamily within the 2 family of the CYP450 superfamily. It metabolizes 5% of all prescribed drugs, such as glipizide, phenytoin, and warfarin. Genetic polymorphisms of CYP2C9 could be used to predict the altered enzyme activity and address the potential effects of metabolized drugs. Individuals exhibiting the most common varient alleles of 2C9, *2 or *3 are at increased risk of metabolizing a drug poorly or not at all. Deficient activityof 2C9 may result in a reduction or lack of therapeutic benefit and an adverse drug reaction due to metabolite buildup in the body. This should be considered prior to initiating or modifying treatment or supplementing with additional drugs.

CYP2C9 genotype testing is required to determine candidacy and the appropriate maintenance dosage for siponimod before treatment initiation. Siponimod is contraindicated in patients who have a CYP2C9*3/*3 genotype. Refer to the siponimod package insert for more details.


Limitations

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

The metabolism of drugs is also influenced by ethnicity, diet, and other medications. All factors should be considered prior to initiating new therapy. This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

Methodology

Real-time polymerase chain reaction (RT-PCR)


References

Siponimod [package insert]. East Hanover, NJ: Novartis Pharmaceutical Corporation; 2019.
Siponimod [package insert]. East Hanover, NJ: Novartis Pharmaceutical Corporation; 2019.

For Providers

Please login to order a test.

 

© 2019  Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2018, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf